Lipoprotein(a) and High Sensitivity C-Reactive Protein among Patients with HIV in Ghana: The Study on Cardiovascular Risk Profile of HIV-Infected Patients on HAART (SCRIPT)
References
- Global Burden of Cardiovascular Diseases Collaboration, Roth GA, Johnson CO, Abate KH, Abd-Allah F, Ahmed M, et al. The Burden of Cardiovascular Diseases Among US States, 1990–2016. JAMA Cardiol. 01 May 2018; 3(5): 375–89.
- Martínez E, Larrousse M, Gatell JM. Cardiovascular disease and HIV infection: host, virus, or drugs? Curr Opin Infect Dis. February 2009; 22(1): 28–34. DOI: 10.1097/QCO.0b013e328320a849
- Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 1999. September 2006; 43(1): 27–34. DOI: 10.1097/01.qai.0000233310.90484.16
- Rawdanowicz J, Pikto-Pietkiewicz W, Marczyńska M. Cardiovascular diseases associated with HIV infection and their management. Kardiol Pol. 2013; 71(11): 1183–7. DOI: 10.5603/KP.2013.0301
- Appiah LT, Sarfo FS, Huffman MD, Nguah SB, Stiles JK. Cardiovascular risk factors among Ghanaian patients with HIV: A cross-sectional study. Clin Cardiol. 30 September 2019; clc.23273. DOI: 10.1002/clc.23273
- Sarfo FS, Nichols M, Agyei B, Singh A, Ennin E, Nyantakyi AD, et al. Burden of subclinical carotid atherosclerosis and vascular risk factors among people living with HIV in Ghana. J Neurol Sci. February 2019; 397: 103–11. DOI: 10.1016/j.jns.2018.12.026
- Appiah LT, Sarfo FS, Agyemang C, Tweneboah HO, Appiah NABA, Bedu-Addo G, et al. Current trends in admissions and outcomes of cardiac diseases in Ghana. Clin Cardiol. October 2017; 40(10): 783–8. DOI: 10.1002/clc.22753
- Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK. Lipoprotein(a): An underrecognized genetic risk factor for malignant coronary artery disease in young Indians. Indian Heart J. 2019; 71(3): 184–98. DOI: 10.1016/j.ihj.2019.04.007
- Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, et al. Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in African Americans and Caucasians: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 17 January 2012; 125(2): 241–9. DOI: 10.1161/CIRCULATIONAHA.111.045120
- Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, et al. Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis from the JUPITER Trial. Circulation. February 2014; 129(6): 635–42. DOI: 10.1161/CIRCULATIONAHA.113.004406
- Guan W, Cao J, Steffen BT, Post WS, Stein JH, Tattersall MC, et al. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: The Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. April 2015; 35(4): 996–1001. DOI: 10.1161/ATVBAHA.114.304785
- Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease. N Engl J Med. Apr 2004; 350(14): 1387–97. DOI: 10.1056/NEJMoa032804
- Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B, et al. C-Reactive Protein Is a Marker for Human Immunodeficiency Virus Disease Progression. Arch Intern Med. 9 Jan 2006; 166(1): 64–70. DOI: 10.1001/archinte.166.1.64
- Masiá M, Bernal E, Padilla S, Graells ML, Jarrín I, Almenar MV, et al. The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis. 1 Nov 2007; 195(1): 167–71. DOI: 10.1016/j.atherosclerosis.2006.09.013
- World Health Organization. Waist circumference and waist-hip ratio: Report of a WHO expert consultation, Geneva, 8–11 December 2008 [Internet]. World Health Organization; 2011 [cited 2020 May 19].
https://apps.who.int/iris/handle/10665/44583 (assessed 19 May 2020). - Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 21 May 2003; 289(19): 2560–72. DOI: 10.1001/jama.289.19.2560
- Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 21 March 2017; 69(11): 1465–508. DOI: 10.1161/CIR.0000000000000470
- Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, et al. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J Am Coll Cardiol. 8 January 2018; 71(2): 177–92. DOI: 10.1016/j.jacc.2017.11.014
- Roberts WL, CDC AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Laboratory tests available to assess inflammation – Performance and standardization: A background paper. Circulation. 21 December 2004; 110(25): e572–576. DOI: 10.1161/01.CIR.0000148986.52696.07
- Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 1 Dec 2010; 31(23): 2844–53. DOI: 10.1093/eurheartj/ehq386
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 18 June 2019; 139(25): e1082–143. DOI: 10.1161/CIR.0000000000000698
- von Eckardstein A. Lipoprotein(a). Eur Heart J. 21 May 2017; 38(20): 1530–2. DOI: 10.1093/eurheartj/ehx233
- Noursadeghi M, Miller RF. Clinical value of C-reactive protein measurements in HIV-positive patients. Int J STD AIDS. June 2005; 16(6): 438–41. DOI: 10.1258/0956462054094006
- Moshage HJ, Roelofs HM, van Pelt JF, Hazenberg BP, van Leeuwen MA, Limburg PC, et al. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun. 30 August 1988; 155(1): 112–7. DOI: 10.1016/S0006-291X(88)81056-8
- Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol. November 2003; 13(10): 674–82. DOI: 10.1016/S1047-2797(03)00053-X
- Schleicher GK, Herbert V, Brink A, Martin S, Maraj R, Galpin JS, et al. Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J. 1 April 2005; 25(4): 688–92. DOI: 10.1183/09031936.05.00067604
- Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PloS One. 2012; 7(9):
e44454 . DOI: 10.1371/journal.pone.0044454 - von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol. 1 February 2001; 37(2): 434–9. DOI: 10.1016/S0735-1097(00)01126-8
- Mauss S, Berger F, Schmutz G, Henke J, Richter WO. Lipoprotein(a) in patients initiating antiretroviral therapy. HIV Med. July 2008; 9(6): 415–20. DOI: 10.1111/j.1468-1293.2008.00574.x
- Byambaa E, Anuurad E, Zhang W, Abbuthalha A, Li X-D, Dotterweich W, et al. HIV Disease Activity as a Modulator of Lipoprotein(a) and Allele-Specific Apolipoprotein(a) Levels. Arterioscler Thromb Vasc Biol. 1 February 2013; 33(2): 387–92. DOI: 10.1161/ATVBAHA.112.300125
- Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. July 1992; 90(1): 52–60. DOI: 10.1172/JCI115855
- Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d’Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS Lond Engl. 23 May 2003; 17(8): 1179–93. DOI: 10.1097/00002030-200305230-00010
- Grinspoon S, Carr A. Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. N Engl J Med. 6 January 2005; 352(1): 48–62. DOI: 10.1056/NEJMra041811
- Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement from the American Heart Association. Circulation. 9 July 2019; 140(2): e98–124. DOI: 10.1161/CIR.0000000000000695
DOI: https://doi.org/10.5334/gh.850 | Journal eISSN: 2211-8179
Language: English
Submitted on: Jun 21, 2020
Accepted on: Oct 18, 2020
Published on: Nov 3, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2020 Lambert Tetteh Appiah, Fred Stephen Sarfo, Samuel Blay Nguah, Mark D. Huffman, Jonathan K. Stiles, Matthew J. Feinstein, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.